FDA Pulls Plug on 1970s Hormone Combo Tablets at Last
Published Date: 5/27/2026
Notice
Summary
The FDA just announced that certain estrogen-androgen combo drugs, like Syntest D.S. and Syntest H.S., aren’t proven effective and can’t be sold unless they have official approval. This affects drug makers and sellers who must stop interstate shipments of these products by June 26, 2026. If you’re involved, it’s time to get compliant or say goodbye to these meds on the market!
Analyzed Economic Effects
2 provisions identified: 0 benefits, 1 costs, 1 mixed.
Manufacturers Must Stop Interstate Shipments
If you make or sell estrogen-androgen fixed-combination drugs (including Syntest D.S., Syntest H.S., Estratest, and Estratest HS, and any identical, related, or similar products covered by DESI 7661), you cannot ship them in interstate commerce unless they are the subject of an approved NDA or ANDA. That prohibition is unlawful to violate as of June 26, 2026, and FDA says it will take enforcement action without further notice against firms that continue to manufacture or ship unapproved products.
Users May Lose Access; Products Found Ineffective
The FDA found that estrogen-androgen fixed-combination products covered by DESI 7661 are not shown to be effective for the labeled menopausal use and cannot be legally shipped without FDA approval. If you take Syntest D.S., Syntest H.S., Estratest, Estratest HS, or a similar unapproved product, you may face reduced availability of those medicines after June 26, 2026, while the safety/effectiveness status and approval are resolved.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10372 — Agency Information Collection Activities; Proposed Collection; Comment Request; Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act
The FDA wants your thoughts on how they collect info about making custom human drugs under special rules (Sections 503A and 503B). This affects pharmacies and drug makers who mix medicines just for patients. You’ve got until July 27, 2026, to share your comments—no cost changes yet, just a chance to help shape the paperwork process!
2026-10371 — Advisory Committee; Drug Safety and Risk Management Advisory Committee; Renewal
The FDA is renewing its Drug Safety and Risk Management Advisory Committee for two more years, keeping it active until May 31, 2028. This committee helps the FDA make smart decisions about drug safety and risks, protecting everyone who uses medicines. No new costs or big changes, just a continued commitment to keeping drugs safe and sound.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
Previous / Next Documents
Previous: 2026-10477 — Renewal of Agency Information Collection Activities: Submission for OMB Review; Comment Requested; Containerized Freight Statistics-Imports and Exports; 3072-0074
The Federal Maritime Commission is asking to keep collecting info on container ship imports and exports, but with some updates. Shipping companies and related businesses should take note and can share their thoughts by June 26, 2026. This helps the government keep track of trade without adding extra hassle or costs.
Next: 2026-10482 — Agency Information Collection Activity: Appointment of Veterans Service Organization as Claimant's Representative and Appointment of Individual as Claimant's Representative
The VA is updating forms that let veterans pick someone to help with their claims, like a Veterans Service Organization or an individual. They want your feedback by July 27, 2026, to make sure the forms are clear and easy to use. This update won’t cost veterans extra money but aims to speed up and improve the claims process.